Super Micro Computer Inc vs 10X Genomics Inc — how do they compare? Super Micro Computer Inc trades at $41.86 (market cap $28.10B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: Super Micro Computer Inc is far larger — about 2.8× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Super Micro Computer Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Super Micro Computer Inc for 19 Days and 10X Genomics Inc for 91 Days on average.
| SMCI | TXG | |
|---|---|---|
Market Cap | $28.10B | $10.07B |
Volume | 38,581,805 | 5,657,286 |
Sector | Technology | Health |
52-Week High | $55.04 | $97.74 |
52-Week Low | $20.53 | $11.48 |
Typical Hold Time | 19 Days | 91 Days |
Enterprise Value | $33.56B | $9.59B |
Signals from Pluang's Aura AI — not financial advice
Super Micro Computer (SMCI) trades at $42.77, down 4.85% on the day, with a bullish technical signal and strong fundamental performance. Recent earnings beats and robust revenue growth to $39.1B in 2026 highlight its AI infrastructure strength. The stock is near its consensus price target of $42.33, with support at $42 and resistance at $44.
Outlook remains positive driven by AI server demand, though risks include margin pressure and a DOJ investigation. Analysts are mixed with 36% buy ratings, but the low P/E of 13.12 offers value if growth sustains. Investors should weigh execution risks against the company's strategic position in expanding AI markets.
10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.
The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →